Literature DB >> 27413701

Overcoming toxicity-challenges in chemoradiation for non-small cell lung cancer.

Wilma Uyterlinde1.   

Abstract

Concurrent chemoradiation (CCRT) is the treatment of choice for locally advanced non-small cell lung cancer (NSCLC) with a modest survival benefit over sequential chemoradiation or radiotherapy (SCRT) alone. However, this benefit is at the cost of increasing acute toxicity such as esophagitis. Previous analysis revealed several predictive parameters in dose-volume and patient characteristics which helped us to identify those patients at risk for severe esophagus toxicity. As a result, supportive care interventions including individualized patient information, dietary guidance, adequate medication, hydration and tubefeeding could be initiated. This paper discusses the challenges in overcoming chemoradiation induced acute esophageal toxicity (AET).

Entities:  

Keywords:  Chemoradiation; management; supportive care; toxicity

Year:  2016        PMID: 27413701      PMCID: PMC4931143          DOI: 10.21037/tlcr.2016.05.03

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  19 in total

1.  Treatment adherence in concurrent chemoradiation in patients with locally advanced non-small cell lung carcinoma: results of daily intravenous prehydration.

Authors:  Wilma Uyterlinde; Chun Chen; Jasper Nijkamp; Marieke Groot Obbink; Jan-Jakob Sonke; Jose Belderbos; Michel van den Heuvel
Journal:  Radiother Oncol       Date:  2014-01-17       Impact factor: 6.280

2.  Radiotherapy and cis-diammine dichloroplatinum (II) as a combined treatment modality for inoperable non-small cell lung cancer: a dose finding study.

Authors:  C Schaake-Koning; H Bartelink; B H Adema; L Schuster-Uitterhoeve; N van Zandwijk
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-03       Impact factor: 7.038

3.  Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer.

Authors:  H Choy; K LaPorte; E Knill-Selby; P Mohr; Y Shyr
Journal:  Semin Radiat Oncol       Date:  1999-04       Impact factor: 5.934

4.  Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.

Authors:  Wilma Uyterlinde; José Belderbos; Claudia Baas; Erik van Werkhoven; Joost Knegjens; Paul Baas; Arthur Smit; Chris Rikers; Michel van den Heuvel
Journal:  Clin Lung Cancer       Date:  2013-07-05       Impact factor: 4.785

Review 5.  Chemoradiation therapy in nonsmall cell lung cancer.

Authors:  Paul Baas; Jose S A Belderbos; Michel van den Heuvel
Journal:  Curr Opin Oncol       Date:  2011-03       Impact factor: 3.645

6.  First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy.

Authors:  José S A Belderbos; Katrien De Jaeger; Wilma D Heemsbergen; Yvette Seppenwoolde; Paul Baas; Liesbeth J Boersma; Joos V Lebesque
Journal:  Radiother Oncol       Date:  2003-02       Impact factor: 6.280

Review 7.  Systematic review of dose-volume parameters in the prediction of esophagitis in thoracic radiotherapy.

Authors:  Jim Rose; George Rodrigues; Brian Yaremko; Michael Lock; David D'Souza
Journal:  Radiother Oncol       Date:  2008-10-22       Impact factor: 6.280

8.  Oral sucralfate in acute radiation oesophagitis.

Authors:  R K Sur; R Kochhar; D P Singh
Journal:  Acta Oncol       Date:  1994       Impact factor: 4.089

9.  Acute esophagus toxicity in lung cancer patients after intensity modulated radiation therapy and concurrent chemotherapy.

Authors:  Margriet Kwint; Wilma Uyterlinde; Jasper Nijkamp; Chun Chen; Josien de Bois; Jan-Jakob Sonke; Michel van den Heuvel; Joost Knegjens; Marcel van Herk; José Belderbos
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-05-05       Impact factor: 7.038

10.  Prognostic parameters for acute esophagus toxicity in intensity modulated radiotherapy and concurrent chemotherapy for locally advanced non-small cell lung cancer.

Authors:  Wilma Uyterlinde; Chun Chen; Margriet Kwint; Josien de Bois; Andrew Vincent; Jan-Jakob Sonke; Jose Belderbos; Michel van den Heuvel
Journal:  Radiother Oncol       Date:  2013-05-03       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.